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1. Introduction
  Tuberculosis (TB) is a major social and economic 
problem around the world, mostly in developing countries, 
especially in the South-East Asia, African and Western 
Pacific regions[1]. According to reports of World Health 
Organization (WHO), over a third of the world’s population 
are infected with TB, and annually about 9 million TB cases 
is reported to be responsible for adult deaths every year, 
more than any other single infectious disease[2]. 
  Mycobacterium bovis Bacille Calmette-Guérin (BCG) 
vaccine has been used for about 80 years as currently the 
sole available administered vaccine against TB[3]. Though 
vaccination of infants and children with BCG has reduced 
several serious TB diseases, unfortunately its efficacy 
against adult pulmonary TB disease is highly unstable. 
Large numbers of field trails have shown that efficacy of 
BCG vary from 0% to approximately 80%[4]. It can also cause 
pathogenicity in immunocompromised patients and prevent 
the use of tuberculin in TB diagnosis[5]. Since TB represents 
a severe danger to public health in spite of the widespread 
use of BCG vaccine, more new effective vaccines or 
vaccination strategies are urgently needed[6]. Considerable 
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efforts are aiming at the development vaccine against 
TB especially using molecular techniques. They include 
recombinant BCG vaccines, live attenuated vaccines, non-
mycobacterial vaccine vectors, DNA vaccines, and subunit 
vaccines, etc. Culture filtrate proteins isolated from MTB are 
mainly using for vaccine candidates[7]. fbpB and esxA genes 
encode major secretory protein antigen 85B (Ag85B) and 
early secretory antigenic target-6 (ESAT-6), respectively. 
Both Ag85B and ESAT-6 are major co-secreted proteins that 
exist in culture filtrates[8,9]. Ag85B which participates in cell 
wall mycolic acid synthesis is the most dominant protein of 
MTB, and is a potent immuno-protective antigen as well as a 
leading drug target[10]. Immunization with Ag85B and ESAT-6 
protein or DNA induces a strong IFN-毭 response and 
antigen-specific CD4+ Th1 cells and CD8+ T cells, and protected 
against TB[11,12].
  Early and rapid diagnosis plays an important role in TB 
disease control, but the microscopic examination is still the 
unique global available diagnostic tool for identifying TB. 
Therefore, the development of simple, sensitive and specific 
methods for diagnosis of TB infections is critical needed[13]. 
Serological test appears to be a promising approach for the 
diagnosis of pulmonary as well as extra-pulmonary TB[14]. 
Ag85B and ESAT-6 are demonstrated as specific antigens 
of MTB as they are absent in most of the nonpathogenic 
mycobacteria and in BCG. They are recognized by immunity 
system of infected host. Thus they could be strong superior 
serodiagnostic antigens to distinguish infected and BCG-
vaccinated individuals with TB[15]. Enzyme-linked 
immunosorbent assay based Ag85B and ESAT-6 is high 
degree of sensitivity (84.1% and 64.9%, respectively) and 
specificity (about 90%) for TB diagnosis, Ag85B-ESAT-6 
fusion protein could have higher sensitivity than single 
antigen accordingly[16].
  In the search for more safer and potent TB vaccines, and 
evaluate specific antigen potential as diagnostic markers, 
we expressed and identified the fbpB-esxA fusing gene in 
Escherichia coli (E. coli) strain and predicted the structure 
and characteristies of recombinant fusion protein by 
bioinformatics methods.
2. Materials and methods 
2.1. Bacterial strains, plasmids, enzymes and culture 
conditions
  Genomic DNA of Mycobacterium tuberculosis (MTB) H37Rv 
was kindly provided by Lab Director Zhu ZY of Affiliated 
Xinhua Hospital of Hainan Medical University. E. coli DH5
毩 (TaKaRa Biotechnology, China) and E. coli BL21 (DE3) 
(Merck-Novagen, Germany) were used as the recipient 
of recombinant plasmids and the host of expressing 
protein. All E. coli strains were grown aerobically on a 
rotary shaker in liquid or on solid (1.5% agar) Luria–
Bertrani (LB) medium at 37 曟. When needed, kanamycin 
(50毺g/mL) was used for selection of recombinant strains. 
Plasmid pET30-a (Merck-Novagen, Germany) were used as 
expression vector respectively. Restriction enzymes (BamH
栺, Sac栺), PrimeSTARTM HS DNA Polymerase and T4 ligase 
were purchased from TaKaRa Biotechnology, China. High 
Fidelity PCR Enzyme Mix was purchased from Fermentas 
Canada. All other chemicals were of an analytical grade.
2.2. Amplification of  fbpB and esxA genes
  Nucleotide sequences of fbpB and esxA genes were 
retrieved from MTB H37Rv genome (GenBank Accession 
No.NC_000962, http://www.ncbi.nlm.nih.gov). PCR was 
performed using MTB H37Rv Genomic DNA as the template 
with following primers: fbpB-F and fbpB-R were used for 
amplification of fbpB gene (reverse direction), and primers 
esxA-F and esxA-R were used for amplification of esxA gene 
(Table 1). Two sets of primers contained BamH栺 and Sac
栺 endonuclease restriction sites. PCR was performed by 
using of High Fidelity PCR Enzyme Mix in a volume of 50 毺L
as follow cycling temperatures: 94 曟 for 5 min, 10 cycles 
(94 曟 30 s; 60 曟 40 s; 72 曟 1 min), 25 cycles (94 曟 30 s; 
65 曟 40 s; 72 曟 1 min), and then 72 曟 for 7 min. The PCR 
products were visualized on a 1% agarose gel stained with 
ethidium bromide.
2.3. Assembly of the fbpB-esxA fusing gene by PCR
  After the first round of PCR, DNA fragments of amplification 
were isolated from agarose gels by using TIANgel midi 
purification kit (TIANGEN, China), according to the 
manufacturer protocol. Linking fbpB and esxA gene with 
(Gly4Ser)3 linker by the use of Gene Splicing by Overlapping 
Extension PCR (SOE-PCR). The fragments encoding the 
fbpB+(Gly4Ser)3 and (Gly4Ser)3+esxA was amplified by second 
round PCR using the primers fbpB-F and fbpB-linker, 
the primers esxA-linker and esxA-R, respectively (Table 
1). We deleted stop codon of the fbpB gene in this study. 
Finally, using the purified fragments of fbpB+(Gly4Ser)3 and 
(Gly4Ser)3+esxA as template, the third round of PCR was 
performed using PrimeSTARTM HS DNA Polymerase as follow 
conditions: 7 cycles (98 曟 10 s; 68 曟 60 s), after 98 曟 20 
s, primers fbpB-F and esxA-R were added, 25 cycles (98 曟 
10 s; 68 曟 60 s).
Table 1 
Primers used in this study.
Primer name Sequence
fbpB-F 5′-CGCGGATCCATGACAGACGTGAGCCGAAAGA
TTC-3′
fbpB-R 5′-TCCGAGCTCTCAGCCGGCGCCTAACGAACTC-
3′
esxA-F 5′-CGCGGATCCATGACAGAGCAGCAGTGGAATT
TCG-3′
esxA-R 5′-TCCGAGCTCCTATGCGAACATCCCAGTGACGT
TG-3′
fbpB-linker 5′-GCCGCTTCCGCCACCGCCGCTTCCACCGCCAC
CGCCGGCGCCTAACGAACTCTGC-3′
esxA-linker 5′-AGCGGCGGTGGCGGAAGCGGCGGTGGCGGCA
GCATGACAGAGCAGCAGTGGAATTTCG-3′
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2.4. Construction of expression plasmid
  PCR products of assembled fbpB-esxA were gel purified 
and digested with BamH栺 and Sac栺 restriction enzymes 
for 16h at 37 曟, and then was ligated into prokaryotic 
expression vector pET30-a (digested with these same 
enzymes) at 16 曟 for overnight resulting in recombinant 
plasmid pET30-fbpB-esxA, and chemically transformed 
into the E. coli DH5毩 cells using standard procedures. 
Colonies were screened by PCR (using primers fbpB-F and 
esxA-R) and restriction endonucleases, and then sequenced 
to confirm that no base changes had been introduced during 
amplification of the DNA.
2.5. Expression of fbpB-esxA fusing gene in E. coli
  The E. coli BL21 (DE3) was employed to express the fusion 
proteins. The recombinant plasmid pET30-fbpB-esxA 
was transformed into competent E. coli BL21 (DE3) cells 
and selected according to the manufacturer’s direction. 
One engineering strain was incubated in the standard 
conditions as described by the manufacturer (Merck-
Novagen, Germany). One mL overnight culture was 
subcultured in 100 mL fresh LB medium at 37 曟 with 250 
rpm shaking until they reached an A600 of 0.5. isopropyl-毬
-D-thiogalactopyranoside (IPTG) was then added to a final 
concentration of 0.5 mM for various induction periods of 1, 2 
and 3 h at 37 曟. After induction, cells were incubated on ice 
and harvested with 5 min of 10 000 g, and then total proteins 
of the induced and control cells were resolved on 12% 
SDS-PAGE with a 1.0-mm-thick gel in a Bio-Rad Mini-
Protein 栻 Electrophoresis System (Bio-Rad, USA). After 
separation, proteins were visualized by 2.5 g/L Coomassie 
brilliant blue G-250 staining, and then destained with 10% 
acetic acid and 25% isopropanol. In order to examine the 
extent of aggregation of the produced, induced cells were 
disrupted by sonication for 5 min on ice and soluble as well 
as insoluble fractions were analyzed using SDS-PAGE as 
described previously. 
2.6. Western blot analysis
  Whole-cell proteins were run on 12% SDS-PAGE and 
transferred to PVDF membrane. After blocking with 5% 
nonfat dry milk, the membrane was probed by incubating 
the membrane with 1÷5000-dilution of mouse anti-
polyhistidine monoclonal HIS-1 antibody (Sigma, USA) 
followed by 1÷7000-dilution of HRP-conjugated goat anti-
mouse IgG antibody (Sigma, USA). The immunoreactive 
protein was visualized by DAB (TIANGEN, China).
2.7. Bioinformatics analysis of Ag85B-ESAT-6 fusion 
protein
  All of amino acid sequences were from the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.
gov) in this study. Basic physical and chemical properties 
were analyzed using Vector NTI Advance 11.0 software 
(Invitrogen, USA). Signal peptides, cleavage sites and 
subcellular location were predicted by the SignalP program, 
TargetP program and TMHMM program, respectively (http://
www.cbs.dtu.dk/). Antigenic epitopes were predicted by 
Abie Pro 3.0 program (http://www.changbioscience.com/
abie/abie.html) and Predicting Antigenic Peptides program 
(http://bio.dfci.harvard.edu/Tools/antigenic.html). Secondary 
structure was predicted by PredictProtein program (http://
www. Predictprotein.org/), COILS program (http://www.
ch.embnet.org/software/COILS_form.html), ANTHEPROT 
2000 software (http://antheprot-pbil.ibcp.fr/), then displayed 
using Geneious Pro 4.8.5 software (Biomatters, USA). 
3. Results 
3.1. PCR amplification of fbpB and esxA genes
 
  fbpB and esxA genes were amplified by PCR (Figure 
1). DMSO has been added to PCR reaction buffer to 
enhance denaturation of GC rich template DNA and 
to aid polymerase extension through the secondary 
structures in this study. Amplification of fbpB generated 
a major DNA fragment with the expected length about 
996 bp, while esxA generated an expected 306 bp. 
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Figure 1. Agarose gel electrophoresis of PCR products of fbpB and 
esxA genes. 
(A) Lane M, the molecular mass markers; lane 1, PCR product of fbpB 
gene.  (B) Lane M, the molecular mass markers; lane 1, PCR product 
of esxA gene.
 
3.2. Construction of the fbpB-esxA fusing gene and 
expression plasmid 
  We gained the fusion gene that contains 1 326 bp by SOE-
PCR (Figure 2A). The fbpB-esxA fusing gene was then cloned 
into pET30-a. The recombinant plasmid pET30-fbpB-esxA 
was identified by PCR and restriction endonuclease (Figure 
2B). The sequencing results demonstrated that the cloned 
fbpB-esxA gene was identical to the published sequence 
(GenBank Accession No. BX842578, GenBank Accession 
No. BX842584) and there was no any change of base pair. 
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Figure 2. Agarose gel electrophoresis of PCR products of the fbpB-
esxA fusing gene and restriction endonuclease analysis of recombinant 
plasmid pET30-fbpB-esxA. 
(A) Lane M, the molecular mass markers; lane 1, PCR product of 
fbpB-esxA fusing gene. (B) Recombinant plasmid pET30-fbpB-esxA 
was identified by restriction endonuclease. Lane M, the molecular 
mass markers; Lane 1, pET30-fbpB-esxA was digested by BamH栺 
and Sac栺.
 
3.3. Expression and identification of Ag85B-ESAT-6 fusing 
proteins
  The Ag85B-ESAT-6 fusing proteins were produced in E. 
coli BL21 (DE3) cells carrying pET30-fbpB-esxA plasmid. 
We attempted to induce the protein at a lower incubation 
temperature (28℃), lower concentration of IPTG (0.1 mM), 
in order to avoid inclusion bodies formation, but it was not 
successful. The Ag85B-ESAT-6  fusing protein was observed 
on Coomassie blue G-250 stained gel as expected about 
50 kDa band (Figure 3A). Analysis of the total and soluble 
fractions of the expressed Ag85B-ESAT-6  fusing protein 
by SDS-PAGE demonstrated that the protein was localized 
mainly in the insoluble fraction (Figure 3B). Western 
blot analysis of the total cells proteins confirmed that the 
observed protein band reacted with the specific antibodies 
(Figure 3C).
3.4. Characteristics and structures of Ag85B-ESAT-6 fusing 
protein from bioinformatics analysis
  The Ag85B-ESAT-6 fusing protein composed 485 amino 
acids with an estimated molecular mass of 50.8 kDa and a 
pI value of 5.36. This fusing protein has a transmembrane 
region (LMIGTAAAVVLPGLVGLAGGA) and no signal peptide, 
locates outside of membrane mostly. Secondary structure 
analysis revealed that the protein contained alpha helix 
(22.1%), beta strand (26.9%), random coil (31.4%) and 
turn (19.6%), respectively. It possessed fourteen potential 
antigenic epitopes larger than six amino acids (Figure 4).
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Figure 3. SDS-PAGE analysis and Western blot identification of the 
Ag85B-ESAT-6 fusing protein expressed in E. coli BL21 (DE3) cells. 
(A) SDS-PAGE analysis of total proteins expressed. Lane M, protein 
molecular mass standards; lane 1, cell lysate of bacteria transformed 
with pET30-fbpB-esxA without induction; lane 2-4, cell lysate of 
bacteria transformed with pET30-fbpB-esxA under 0.5 mM IPTG 
induction for 1 h, 2h, 3h, respectively. (B) SDS-PAGE analysis of 
soluble and insoluble fractions proteins expressed. Lane M, protein 
molecular mass standards; lane 1, induced pET30- fbpB-esxA by 
0.5 mM IPTG for 1 h, pellet; lane 2, induced pET30-fbpB-esxA by 
0.5 mM IPTG for 1 h, supernatant. (C) Western blot analysis of the 
Ag85B-ESAT-6 fusing protein. lane 1, negative control; lane 2, the 
Ag85B-ESAT-6 fusing protein. 
 
Figure 4. Prediction of secondary structure, subcellular location and 
possible epitopes of the Ag85B-ESAT-6 fusion protein.
 : alpha helix, : beta strand, 
: random coil,  : turn,  : transmembrane 
region, : antigenic region.
4. Discussion 
  TB is a serious public health problem throughout the world 
due to the occurrence of multi-drug resistant-TB, and due 
to its association with human immunodeficiency infection. 
Treatment, diagnosis, and prevention for TB are out of date 
and inadequate[17,18]. Most attempts to develop TB vaccines 
have resulted in low activity in clinical application. The 
strategy based on fusion TB antigen proteins for developing 
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novel subunit vaccines could promote efficient protection[19]. 
IFN-毭 produces CD4 T cells and protective immunity, and 
may induce powerful cell-mediated response. So the fusion 
protein consisting of Ag85B and ESAT-6 is produced and 
evaluated as a potential tuberculosis subunit vaccine[20]. 
Both Ag85B and ESAT-6 are deleted from BCG, and therefore 
are particularly promising candidates for development of 
serodiagnostic assays to detect active TB[21-24].
  In the present work, we used SOE-PCR to obtain the 
fbpB-esxA fusing gene. SOE-PCR is a technique that DNA 
fragments are fused together by PCR without restriction 
digestion. Primer for each fragment is designed to overlap 
sequences on the other fragment. Mix PCR products of the 
two fragments, and amplification using outer primers result 
in the production of fusion DNA. Contrasting with other 
methods, it is simple, quick and convenient[25].
  To study the possible function of Ag85B-ESAT-6 fusing 
protein, pQE-30 vector (Qiagen, Germany) was first used 
for the expression of the fusing protein in E. coli M15. 
However, this approach is not successful in our study. 
Therefore, plasmid pET30-a was chosen because it 
provides the N-terminal 6×His Tag and S- Tag sequence 
to the expressed proteins, which could facilitate protein 
purification by affinity purification methods. Tag-encoded 
protein sequences can be removed from the resulting fusion 
proteins by cleavage with enterokinase[26]. The Ag85B-
ESAT-6 fusing protein band of interest is absent from the 
soluble fraction by SDS-PAGE, but is obviously detected in 
the insoluble fraction. It is thus not possible to purify the 
protein in a soluble form, so we could change conditions for 
expression or refolding of protein from the insoluble fraction 
in the future.
  We predicted potential antigenic epitopes of the Ag85B-
ESAT-6 fusing protein by using of bioinformatics methods, 
and demonstrated that the protein reserved virgin 
immunogenicity of single antigen. Therefore, the Ag85B-
ESAT-6 fusing protein is a potential and suitable molecular 
target to develop new TB vaccines and diagnostic reagents.
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